Skip to content

Substance Use Disorder in Chemsex Practice

Substance Use Disorder in Chemsex Practice: Evaluation of the Prevalence of the Disorder Among Users Via an Online Self-questionnaire

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06476873
Acronym
TU CHEMSEX
Enrollment
1000
Registered
2024-06-27
Start date
2024-07-01
Completion date
2025-08-30
Last updated
2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction Chemical, Use, Substance

Brief summary

The main aim of this descriptive cross-sectional study is to assess the prevalence of chemsex substance use disorder among chemsexers via an online self-questionnaire.

Detailed description

Chemsex appeared in Europe around 2006 and in France in 2010. It involves the use of psychoactive substances in a sexual context to enhance, initiate, facilitate or prolong sexual intercourse through the psychoactive effects of the molecules consumed. These molecules are essentially synthetic cathinones, GHB/GBL, MDMA, methamphetamines, cocaine and ketamine. These products are often used in combination with erectile dysfunction treatments (side effects of the molecules). This practice is thought to affect almost 20% of MSM. This use has numerous social, somatic, psychiatric and addictive consequences. Studies have mainly focused on infectious risks, psychiatric complications (e.g. anxiety and depression) or the prevalence of this phenomenon. However, no study has assessed the prevalence of chemsex-related substance use disorders among these users.

Interventions

BEHAVIORALOnline self-questionnaire.

Descriptive, cross-sectional study This study is aimed at adult chemsex users over the last 12 months (having experimented with chemsex at least once over the last 12 months) and with a good understanding of French. An online LimeSurvey-type self-questionnaire will be accessible via a URL link to collect and secure the data. A presentation of the study, information on chemsex and help and care services, as well as the information note will be available. The questionnaire will be distributed via a QR code, giving direct access to the study's web page, or directly via the web link. Posters and flyers will be used in hospitals and/or private clinics, addictology centers, STI prevention and screening centers and associations, as well as via social networks, dating apps and sites, and the online and print press.

Sponsors

Centre Hospitalier Charles Perrens, Bordeaux
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

cohort

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Be 18 years of age or older. * Proficiency in written French * Have practised chemsex at least once in the last 12 months. * Agree to participate in the study.

Exclusion criteria

* Have not experimented with chemsex in the last 12 months * Participation in other ongoing research * Insufficient written comprehension of French

Design outcomes

Primary

MeasureTime frameDescription
DSM-5 diagnosis of substance use disorder for chemsex.1 dayAssessment of the prevalence of chemsex substance use disorder among chemsexers via an online self-questionnaire.

Secondary

MeasureTime frameDescription
Describing the sociodemographic characteristics of this population1 daySocio-demographic characteristics
Describing the consumption practices of this population1 dayConsumption practices
Describing the sexual practices of this population1 daySexual practices
Explore the existence of chemsex use disorder as a clinical entity in its own right1 dayDSM-5 diagnostic criteria for substance use disorder, adapted to assess chemsex addiction as a single clinical entity

Countries

France

Contacts

Primary ContactMelina FATSEAS
melina.fatseas@chu-bordeaux.fr05 24 54 90 00
Backup ContactHelen SAVARIEAU
hsavarieau@ch-perrens.fr05 56 56 35 56

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026